Keppra Pediatric Epilepsy Claim Clears FDA Under Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Indication provides for add-on treatment of children ages four years and up with partial onset epileptic seizures. Firm expects sales force expansion to be completed by year-end.